Home / Business and Economy / Gland Pharma's Profit Skyrockets 96% on Strong Revenue Growth
Gland Pharma's Profit Skyrockets 96% on Strong Revenue Growth
15 May
Summary
- Fourth-quarter net profit soared 96.6% to ₹366.6 crore.
- Revenue increased by 22.3% year-on-year to ₹1,742.7 crore.
- A final dividend of ₹20 per equity share was recommended for FY26.
Hyderabad-based Gland Pharma Ltd announced a significant financial uplift for its fourth quarter, with consolidated net profit jumping 96.6% year-on-year to ₹366.6 crore. This substantial gain stemmed from a 22.3% increase in revenue, which reached ₹1,742.7 crore in the period.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw a robust 47.6% year-on-year increase, climbing to ₹512.9 crore. The company's EBITDA margin also expanded to 29.4%. Gland Pharma's strategic investments in research and development, totaling ₹50.6 crore for the quarter, continue to support complex product development and filings.
The Contract Development and Manufacturing Organization (CDMO) business proved to be a strong contributor, accounting for 46% of revenues and showing a 36% year-on-year growth in the fourth quarter. The company successfully launched five new molecules in the US during the quarter, enhancing its market presence.
Looking ahead, the board has recommended a final dividend of ₹20 per equity share for FY26, pending shareholder approval. Despite this positive financial news, Gland Pharma's shares closed at ₹1,861.00 on the BSE, marking a 1.80% decrease.
